Advertisement

Advertisement
Multiple Myeloma
Immunotherapy

FDA Grants Accelerated Approval to Belantamab Mafodotin-blmf for Pretreated Patients With Relapsed or Refractory Multiple Myeloma

On August 5, the U.S. Food and Drug Administration (FDA) granted accelerated approval to belantamab mafodotin-blmf (Blenrep)...

Lymphoma
Immunotherapy

Anti-CD30 CAR T-Cell Therapy for Patients With Relapsed or Refractory Hodgkin Lymphoma

In a pooled analysis of two parallel single-center phase I/II studies reported in the Journal of Clinical Oncology, Ramos et al found that...

Pancreatic Cancer

Addition of Pegvorhyaluronidase Alfa to Nab-paclitaxel and Gemcitabine in Hyaluronan-High Metastatic Pancreatic Cancer

In the phase III HALO 109-301 trial reported in the Journal of Clinical OncologyEric Van Cutsem, MD, PhD, and colleagues found that the addition...


Advertisement
Hepatobiliary Cancer
Immunotherapy

Combination Immunotherapy in Advanced Biliary Tract Cancers

In a subgroup analysis of an Australian phase II trial reported in JAMA Oncology, Klein et al found that the combination of nivolumab and ipilimumab...

COVID-19

ASCO Coronavirus Resources

As the coronavirus (COVID-19) continues to spread, ASCO is committed to providing the most current information and resources to its members and the larger oncology...

Advertisement




Breast Cancer

Sara A. Hurvitz, MD, on Breast Cancer: Four Major Studies on Trastuzumab, Pertuzumab, Anthracyclines, and Chemotherapy De-escalation

Lymphoma

Outcomes With PET-Directed Therapy for Limited-Stage DLBCL

As reported in the Journal of Clinical Oncology by Daniel O. Persky, MD, and colleagues, the phase II Intergroup National Clinical Trials Network Study S1001 has shown good outcomes with positron-emission tomography (PET)-directed therapy in patients with limited-stage diffuse large B-cell lymphoma ...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Breast Cancer

Nancy U. Lin, MD, on Metastatic Breast Cancer: Tucatinib, Trastuzumab, and Capecitabine

Gynecologic Cancers
Immunotherapy

Avelumab for Patients With Gestational Trophoblastic Tumors Resistant to Single-Agent Chemotherapy

In the French phase II TROPHIMMUN trial reported in the Journal of Clinical Oncology, Benoit You, MD, PhD, and colleagues found that avelumab normalized human chorionic gonadotropin (hCG) levels in approximately half of women with gestational trophoblastic tumors resistant to single-agent...

San Antonio Breast Cancer Symposium to Be Held Virtually

Today, the San Antonio Breast Cancer Symposium (SABCS) Executive Committee announced that the San Antonio Breast Cancer Symposium will take place in 2020. However, in response to the novel coronavirus (COVID-19) global pandemic, the Executive Committee has made the decision—out of necessity to...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Leukemia

Farhad Ravandi-Kashani, MD, on Acute Myeloid Leukemia: AMG 330 in Patients With Relapsed or Refractory Disease

Myelodysplastic Syndromes

Pevonedistat Plus Azacitidine May Be of Benefit in Higher-Risk Myelodysplastic Syndromes

In higher-risk myelodysplastic syndromes (MDS), a global phase II open-label study found that the combination of pevonedistat plus azacitidine was associated with a trend toward improved event-free survival and numerically longer overall survival, as compared with azacitidine alone, according to...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...